ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Cygnal Therapeutics launches with $65 million in funding

by Megha Satyanarayana
October 12, 2019 | APPEARED IN VOLUME 97, ISSUE 40

 

Cygnal Therapeutics has emerged from stealth mode with $65 million in funding, mostly from the venture capital firm Flagship Pioneering. The Cambridge, Massachusetts–based biotech firm focuses on exoneurobiology, the neurobiology of the peripheral nervous system. CEO Pearl Huang says nerves outside the central nervous system play a significant role in disease and that Cygnal’s multifaceted platform will allow it to find small molecules and build biologics that affect the activity of these nerves.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment